Skip to main content
Caplight Logo









Gradient Denervation Technologies

Gradient Denervation Technologies

Private
ParisHealthcare & Life Scienceshttps://gradientdenervation.com/

Last Round

Series A

Sep 7, 2023

Total Funding Raised

$19.15M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Gradient Denervation Technologies is a medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription

AI Layer

Non-AI

Keywords

pulmonary artery denervationPADNpulmonary hypertensiontherapeutic ultrasounddenervation therapycatheter ablationminimally invasive deviceinterventional cardiologycardiovascular deviceMedTechFDA Breakthrough Devicenerve ablationclinical-stage companyGroup 2 pulmonary hypertension

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gradient Denervation Technologies Comparables

Compare Gradient Denervation Technologies with similar companies based on industry and business-model similarity.

Gradient Denervation Technologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cortex, Inc.
88%
Pulnovo Medical
85%
Otsuka Holdings
70%

Gradient Denervation Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 7, 2023
SeedSep 17, 2020

Key People

Founding team and executive leadership

Martin Grasse

CEO

Executive Team

David Amaoua

Chief Technology Officer

Executive Team

Julie Messer

Chief Operating Officer

Executive Team

Gradient Denervation Technologies Investors

Notable investors and investment history

Gradient Denervation Technologies investors
InvestorRounds
Asabys PartnersSeries A
Thuja CapitalSeries A
Sofinnova PartnersSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 4, 2.5x the trailing average.

  • May 20, 2026

    Grew 19% QoQ, from 16 to 19 employees.

Gradient Denervation Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gradient Denervation Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gradient Denervation Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range18
Year Founded2020
Last FundingSep 7, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?